J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on July 30. The
Tag: VRTX
Vertex Pharmaceuticals (VRTX) Receives a Hold from Maxim Group
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Veracyte (NASDAQ: VCYT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research
Vertex Pharmaceuticals (VRTX) Received its Third Buy in a Row
After Jefferies and Goldman Sachs gave Vertex Pharmaceuticals (NASDAQ: VRTX) a Buy rating last month, the company received another Buy,
J.P. Morgan Believes Vertex Pharmaceuticals (NASDAQ: VRTX) Won’t Stop Here
In a report issued on July 21, Cory Kasimov from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX
Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Maxim Group analyst Jason McCarthy maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares
Vertex Pharmaceuticals (VRTX) Received its Third Buy in a Row
After RBC Capital and Morgan Stanley gave Vertex Pharmaceuticals (NASDAQ: VRTX) a Buy rating last month, the company received another